Initially, we accumulated LJPC between $2.30 and $2.50 in November of 2019. The buying opportunity came after LJPC announced the discontinuation of its research and development program and the … [Read more...] about La Jolla Pharmaceuticals (Nasdaq: LJPC) Investment Update
Verastem (VSTM) reported earnings on May 9th after the close of the American market and proceeded to plunge 28% during Friday's trading session. What was the cause of this selloff? Here are three big … [Read more...] about Verastem’s Earnings: Is It a Buy Now?
The trade talks between the U.S. and Chinese officials have come and gone leaving no trade deal in place. While U.S markets were not rocked as hard as Asia's it was a still a relatively bloody week. … [Read more...] about Biopharma Stock Watch May 13th-17th
On Wednesday, May 8th, Eyepoint Pharmaceuticals (EYPT) will be releasing its commercial and financial updates for the 1st quarter of 2019. Eyepoint is a commercial-stage specialty pharmaceuticals … [Read more...] about Earnings Alert: Eyepoint Pharmaceuticals and Alimera Sciences